NCT04818138Terminated
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
Canadian Atopic Dermatitis Cohort for Translational Immunology and Imaging (CACTI) With a Nested BROadband vs Narrowband photoTherapy for Eczema (BRONTE) Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Reason given: End of funding period.
Brief summary (registry, in English)
Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different bacteria. Despite many recent gains in the understanding of eczema, a lot needs to be learned. There is little evidence to select between some of the older treatments that are available now. Even the newest targeted therapy does not clear most patients' skin. In order to improve the understanding of eczema, how to treat it now, and to enable discovery of new treatments, the investigators plan to enroll patients into a large study at three centres in Canada (University of Toronto, McGill University and University of British Columbia). The study is called the Canadian Atopic Dermatitis Cohort for Translational Immunology and Imaging (CACTI). In this study, the investigators will collect data on how severe participants' eczema is and what treatments they use. For participants who give permission, the investigators will collect blood and skin biopsy samples to study the mechanisms underlying their disease. The investigators will test to see which form of phototherapy (Broadband or Narrowband Ultraviolet B phototherapy) works best for eczema in a randomized clinical trial. The investigators will also use advanced imaging techniques to visualize the skin. This trial registry entry, including the description of the treatment arms and outcomes, refer to the nested BROadband vs Narrowband photoTherapy for Eczema clinical trial.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 69 (actual)
- First submitted
- 23 Mar 2021
- Start date
- 27 Sept 2021
- Primary completion date
- 5 Jun 2025
- Lead sponsor
- Women's College Hospital
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT04818138
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with phototherapy or oral systemic immune-modulating agents (cyclosporine, methotrexate, azathioprine, mycophenolate) less than 30 days before baseline.
- Treatment with systemic biologic (dupilumab) or experimental therapeutic less than 90 days before baseline.
- Current treatment with oral or intramuscular corticosteroids within 30 days prior to baseline. Topical, intralesional or inhaled corticosteroids are allowed.
- Participating in a clinical trial assessing an investigational agent for atopic dermatitis (topical, systemic or device) within 90 days prior to enrollment.
Who the study is looking for
- Atopic dermatitis according to the Hanifin and Rajka criteria.
- Validated Investigator Global Assessment score of 3 or 4 out of 4
- Eczema Area and Severity Index (EASI) score ≥7.1
- Moderate to severe disease as above despite an adequate trial of topical therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Women's College Hospital | Toronto | Canada | Unknown status |
Related publications
- Narrowband versus broadband ultraviolet B phototherapy for adults with moderate-to-severe atopic dermatitis: a randomized controlled trial.Br J Dermatol · 2026 · PMID 42035246
This page is information, not medical advice. Discuss any trial with your doctor.